Amgen - AMGN Stock Forecast, Price & News

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Stock Up 0.0 %

Shares of NASDAQ:AMGN traded up $0.04 during midday trading on Friday, reaching $248.39. The company had a trading volume of 3,460,877 shares, compared to its average volume of 3,119,200. The company has a quick ratio of 1.17, a current ratio of 1.53 and a debt-to-equity ratio of 14.76. The business's 50 day moving average price is $244.79 and its 200 day moving average price is $240.40. The stock has a market cap of $132.87 billion, a PE ratio of 21.05, a P/E/G ratio of 2.04 and a beta of 0.56. Amgen has a 1-year low of $198.64 and a 1-year high of $258.45.

Amgen (NASDAQ:AMGN - Get Rating) last released its earnings results on Thursday, August 4th. The medical research company reported $4.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.40 by $0.25. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.53 billion. Amgen had a return on equity of 218.34% and a net margin of 24.92%. Amgen's quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.38 earnings per share. Research analysts forecast that Amgen will post 17.42 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 8th. Investors of record on Thursday, August 18th will be given a $1.94 dividend. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.12%. The ex-dividend date of this dividend is Wednesday, August 17th. Amgen's dividend payout ratio is currently 65.76%.

Analysts Set New Price Targets

Several research firms have recently issued reports on AMGN. Morgan Stanley raised their price target on Amgen from $239.00 to $253.00 and gave the stock an "equal weight" rating in a research report on Friday, July 15th. Atlantic Securities reduced their target price on Amgen from $190.00 to $182.00 and set an "underweight" rating on the stock in a report on Tuesday. Oppenheimer reiterated a "buy" rating and set a $290.00 target price on shares of Amgen in a report on Wednesday. Piper Sandler lifted their target price on Amgen from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Friday, August 5th. Finally, StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a report on Monday. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $245.14.

Insider Activity at Amgen

In other Amgen news, Director R Sanders Williams sold 600 shares of the business's stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $250.00, for a total transaction of $150,000.00. Following the transaction, the director now owns 5,501 shares of the company's stock, valued at $1,375,250. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.46% of the stock is owned by company insiders.